Informazioni sul dominio e sul sito Web:
spesolimab.it
Nome del dominio - spesolimab.it
Titolo del sito - spesolimab.it
Domain spesolimab.it viene reindirizzato a https://www.boehringer-ingelheim.com
Posizione GEO del sito
Posizione Paese - France
Fornitore - Nameshield SAS
Site Logo
indirizzo IP:
Server dei nomi di dominio:
ns2.observatoiredesmarques.fr obs.ns1.fr ns3.nameshield.net
Tutti i record:
☆ spesolimab.it. 21600 IN TXT "v=spf1 include:_spf.boehringer-ingelheim.com -all"
☆ spesolimab.it. 21600 IN A 81.92.80.56
☆ spesolimab.it. 21600 IN A 81.92.80.55
☆ spesolimab.it. 21600 IN MX 10 mail1.boehringer-ingelheim.com.
☆ spesolimab.it. 21600 IN MX 10 mail4.boehringer-ingelheim.com.
☆ spesolimab.it. 21600 IN MX 10 mail2.boehringer-ingelheim.com.
☆ spesolimab.it. 21600 IN MX 10 mail3.boehringer-ingelheim.com.
☆ spesolimab.it. 21600 IN NS ns2.observatoiredesmarques.fr.
☆ spesolimab.it. 21600 IN NS ns3.nameshield.net.
☆ spesolimab.it. 21600 IN NS obs.ns1.fr.
☆ spesolimab.it. 21600 IN SOA obs.ns1.fr. technical.nameshield.net. 2023012319 28800 7200 604800 7200
Brief facts about spesolimab:
Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody used for the treatment of generalized pustular psoriasis. It is an interleukin-36 receptor antagonist. It is given via injection into a vein. The most common adverse reactions include fatigue, nausea and vomiting, headache, pruritus and prurigo, bruising, and urinary tract infection. It was approved for medical use in the United States in September 2022, and in European Union in December 2022. The US Food and Drug Administration considers it to be a first-in-class medication.
© DMS 2011-